CompletedNCT04872842Updated Nov 8, 2022

Establishment of Online Registration Platform for Unruptured Intracranial Aneurysms Based on 100 Regional Medical Centers in China and Population Follow-up Study

An observational study in Intracranial Aneurysm, sponsored by Beijing Tiantan Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Beijing Tiantan Hospital · Observational

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 1,000
Ages: 18 Years to 75 Years
Sex: All

Study summary

In this study, 20 regional neurosurgery centers across the country will be included, and the study cohort will be constructed on the basis of the IARP-CP cohort.The artificial intelligence platform was used to analyze the clinical, morphological, hemodynamics, aneurysm wall characteristics and other factors of unruptured aneurysms, as well as the relationship between these factors and the risk of aneurysm instability, seek the potential risk factors, and finally establish a multi-dimensional prediction model of rupture risk of intracranial aneurysms.

Conditions studied

Intracranial Aneurysm

Browse trials for

Keywords

intracranial aneurysm
online registration platform
artificial intelligence
multidimensional model

In context

Intracranial Aneurysm

427 studies on the registry are indexed under Intracranial Aneurysm; 115 are open to participants now.

This study's enrollment of 1,000 is above the median of 200 across 198 observational studies indexed under Intracranial Aneurysm.

Browse Intracranial Aneurysm studies →

Lead sponsor

Beijing Tiantan Hospital is the lead sponsor of 465 studies on the registry; 282 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 75 Years
Sexes eligible: All
Sampling method: Non-probability sample

Study population

Chinese

Inclusion criteria

18-75 years old;
At least one unruptured intracranial aneurysm was found by CTA;
No relevant symptoms, receiving non-operative and conservative observation treatment;
Signing the informed consent.

Exclusion criteria

Exclusion Criteria:

Other cerebrovascular structural lesions (such as cerebrovascular malformation and arteriovenous fistula) or craniocerebral tumors;
Fusiform or dissecting aneurysms;
Traumatic, mycotic and atrial myxoma associated aneurysms;
Suffering from systemic connective tissue diseases, such as polycystic kidney disease;
Expectant survival of no more than 3 years due to other diseases or poor general conditions;
Patients refuse to follow up or cannot communicate with them due to mental diseases;
Pregnant women or participating in other aneurysm related studies.

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 1,000 participants (actual)
Target follow-up: 2 Years
Patient registry: Yes

Groups and cohorts

unstable intracranial aneurysms
Unstable intracranial aneurysms are defined as the intracranial aneurysms that grows or ruptures.
Other: Obervation
stable intracranial aneurysms
Stable intracranial aneurysms are defined as the intracranial aneurysms that have no significant morphological changes.
Other: Obervation

Interventions

OtherObervation
This study is an observational study without any intervention

What researchers measure

Primary outcomes

Aneurysm rupture
Time frame: 2 years

Secondary outcomes

Aneurysm growth
Time frame: 2 years

Study locations

1 site

Beijing Tiantan Hospital
Beijing, Beijing, China

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT04872842
Lead sponsor: Beijing Tiantan Hospital
Collaborators: Beijing Hospital, Peking University Third Hospital, Beijing Sanbo Brain Hospital, Beijing Chao Yang Hospital, Binzhou Renmin Hospital, Fujian Medical University Union Hospital, First Affiliated Hospital of Fujian Medical University, Guangzhou Red Cross Hospital, The First Affiliated Hospital of Haerbin Medical University, The Affiliated Hospital of Qingdao University, Shanxi Provincial People's Hospital, Beijing Tsinghua Changgeng Hospital, RenJi Hospital, Sichuan Provincial People's Hospital, Wuhan Union Hospital, China, The Affiliated Hospital of Kunming Medical University, Beijing Unimed Technology Company
Responsible party: Wang Shuo (Director of Department of Cerebrovascular Neurosurgery, Beijing Tiantan Hospital) — Principal investigator
First posted: May 5, 2021
Start date: Sep 1, 2021
Primary completion: Mar 1, 2022
Completion: May 1, 2022
Last update: Nov 8, 2022

Study contacts

Shuo Wang, MD

principal investigator · Beijing Tiantan Hospital

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Intracranial Aneurysm→

Other studies from this sponsor

Beijing Tiantan Hospital

Start the discussion